Johnson & Johnson secured a major legal victory when the Delaware Supreme Court voided a substantial portion of a $1 billion damages award tied to its 2019 agreement to acquire Auris Health. The court held that J&J had not materially breached the merger agreement’s covenants, reducing its potential payout exposure by more than 60%. By overturning the original Court of Chancery decision, which had found J&J liable for withholding certain clinical data, J&J’s contingent liability on its balance sheet falls from roughly $1 billion to under $400 million. Investors will view this ruling as a boost to J&J’s free cash flow trajectory and as evidence of the company’s disciplined approach to acquisition due diligence.

J&J CEO and Chairman Joaquin Duato used the 44th Annual J.P. Morgan Healthcare Conference to reaffirm the company’s strategy for accelerated growth. Duato noted that J&J outperformed its sector peers in 2025 and projects revenue growth to exceed 2025 levels in 2026, with visibility to double-digit top-line expansion in the latter part of the decade. He highlighted J&J’s aspiration to surpass $100 billion in annual sales, driven by strength in pharmaceuticals—particularly immunology and oncology—and sustained momentum in medical devices and consumer health. Duato emphasized disciplined capital allocation, targeting mid-single-digit operating margin expansion, and doubling down on R&D investments to bolster the late-stage pipeline.

Through its venture arm JJDC, Johnson & Johnson took a minority equity stake in Distalmotion’s DEXTER robotic surgery platform following the latter’s $150 million Series G funding round. The investment underscores J&J’s commitment to the fast-growing ambulatory surgery center (ASC) segment, where DEXTER has performed over 3,000 procedures across hernia repair, cholecystectomy and benign hysterectomy. By aligning with Distalmotion’s open-architecture design—compatible with existing visualization systems—J&J aims to accelerate adoption of soft-tissue robotics outside hospital settings. The move complements J&J’s broader robotics strategy and could create cross-selling opportunities with its endoscopy and visualization product lines.